Open AccessCurrent Perspectives for Oral Hypoglycemic Agents with Clinical Evidence of Larger Studies
Author(s) -
Hiroshi Bando
Publication year - 2021
Publication title -
diabetes research
Language(s) - English
Resource type - Journals
ISSN - 2379-6375
DOI - 10.17140/droj-7-e016
Subject(s) - semaglutide , medicine , sitagliptin , dulaglutide , hazard ratio , exenatide , myocardial infarction , heart failure , mace , linagliptin , sitagliptin phosphate , dipeptidyl peptidase 4 , cardiology , diabetes mellitus , endocrinology , type 2 diabetes , metformin , insulin , liraglutide , confidence interval , conventional pci
Current reports for oral hypoglycemic agents (OHAs) are described. As to the association of dipeptidyl peptidase-4 inhibitors (DPP4i) and bullous pemphigoid (BP), odds ratio (OR) was vildagliptin 5.08, linagliptin 2.87, sitagliptin 1.29 (not significant). Regarding the comparative study between SGLT2i and DPP-4i, SGLT2i group showed lower hazard ratio (HR) as MACE 0.76, myocardial infarction 0.82, cardiovascular death 0.60, heart failure 0.43, all-cause mortality 0.60. Semaglutide showed reduced OR for cardiovascular death than exenatide 0.47, dulaglutide 0.46, albiglutide 0.45, lixisenatide 0.43. SGLT2i showed reduction risk of HR for MACE 0.90, hospitalization for heart failure (HHF)/cardiovascular death 0.78, renal outcomes 0.62.